Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | cDCs | 0.252088 | 7.93e-04 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | B cells | 0.290642 | 4.20e-45 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | CD4+ T cells | 0.320746 | 0.00e+00 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | NK cells | 0.410176 | 0.00e+00 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | CD8+ T cells | 0.330806 | 0.00e+00 |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | Relapsed B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | anti-CD19 CAR-T | NA | Malignant cells | 0.269753 | 9.07e-10 |
PMID34715028 | patients | Tumor tissue | Kidney cancer | Clear cell renal cell carcinoma (ccRCC) | Immunotherapy | nivolumab | post | CD8+ T cells | 0.440855 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | -0.28103 | 2.10e-09 |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | post | NK cells | -0.28735 | 1.18e-43 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | Malignant cells | 0.381464 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | CD4+ T cells | 0.305614 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | NK cells | 0.449999 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | B cells | -1.01196 | 1.82e-05 |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA | Malignant cells | 0.429823 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
APBB1IP | tfdimers__MD00364 | WT1 (directAnnotation). |
APBB1IP | hdpi__GTF3C2 | GTF3C2 (directAnnotation). |
APBB1IP | metacluster_198.3 | ZFP64 (directAnnotation). |
APBB1IP | transfac_pro__M08005 | TCFL5 (inferredBy_Orthology). |
APBB1IP | kznf__ZNF548_Imbeault2017_OM_RCADE | ZNF548 (directAnnotation). |
APBB1IP | metacluster_133.1 | ZNF304; ZNF304; ZSCAN22 (directAnnotation). |
APBB1IP | hocomoco__EGR4_HUMAN.H11MO.0.D | EGR4 (directAnnotation). |
APBB1IP | transfac_pro__M03876 | ZBTB33 (directAnnotation). |
APBB1IP | transfac_pro__M04646 | FOXN4 (directAnnotation). |
APBB1IP | metacluster_126.2 | ZBTB4; ZBTB4 (directAnnotation). |
APBB1IP | kznf__ZBTB14_Schmitges2016_RCADE | ZBTB14 (directAnnotation). |
APBB1IP | kznf__ZNF2_Imbeault2017_OM_RCADE | ZNF2 (directAnnotation). |
APBB1IP | taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNNCGGAAGN_CAP_repr | E2F1; ELK1 (directAnnotation). |
APBB1IP | transfac_pro__M07329 | SP7 (directAnnotation). |
APBB1IP | transfac_pro__M04617 | ZBTB7A (directAnnotation). |
APBB1IP | transfac_pro__M07436 | WT1 (directAnnotation). |
APBB1IP | transfac_pro__M01858 | TFAP2B (directAnnotation). |
APBB1IP | metacluster_66.4 | ARNT2; NR0B1; NR0B1; ZSCAN5A; ZSCAN5A (directAnnotation). ARNT2 (inferredBy_Orthology). |
APBB1IP | transfac_pro__M05463 | ZIM2 (directAnnotation). |
APBB1IP | transfac_pro__M06340 | ZNF790 (directAnnotation). |
APBB1IP | jaspar__MA0185.1 | DEAF1 (inferredBy_Orthology). |
APBB1IP | metacluster_35.2 | EGR1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF3; ELF4; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS1; ETS2; ETV1; ETV1; ETV5; ETV5; ETV6; FLI1; FLI1; GABPA; GABPA; GABPA; GABPB1; GABPB1; GABPB1; ZBTB7A (directAnnotation). ELF2; ELF2; ERG; ERG; ETS2; FLI1; GABPA; IKZF3; SPIC (inferredBy_Orthology). |
APBB1IP | transfac_pro__M01783 | SP2 (directAnnotation). |
APBB1IP | metacluster_135.11 | NR2C2 (directAnnotation). |
APBB1IP | transfac_pro__M07437 | ZBTB2 (directAnnotation). |
APBB1IP | taipale_tf_pairs__RFX3_SREBF2_NNRGYAACNTCACGTGAY_CAP_repr | RFX3; SREBF2 (directAnnotation). |
APBB1IP | metacluster_90.3 | ESRRA; ESRRA; ESRRB; NR5A1 (directAnnotation). ESRRA; NR5A1; NR5A1; NR5A2; NR5A2 (inferredBy_Orthology). |
APBB1IP | tfdimers__MD00204 | GABPA; NKX2-1 (directAnnotation). |
APBB1IP | kznf__ZNF777_Imbeault2017_RP_ChIP-seq | ZNF777 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |